title: Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
abstract: BACKGROUND
  As recently demonstrated, random allocation to rosuvastatin results in large relative risk reductions for first cardiovascular events among apparently healthy men and women with low levels of low-density lipoprotein cholesterol but elevated levels of high-sensitivity C-reactive protein. However, whether the absolute risk reduction among such individuals justifies wide application of statin therapy in primary prevention is a controversial issue with broad policy and public health implications.
  
  
  RESULTS
  Absolute risk reductions and consequent number needed to treat (NNT) values were calculated across a range of end points, timeframes, and subgroups using data from Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER), a randomized evaluation of rosuvastatin 20 mg versus placebo conducted among 17 802 apparently healthy men and women with low-density lipoprotein cholesterol <130 mg/dL and high-sensitivity C-reactive protein >or=2 mg/L. Sensitivity analyses were also performed to address the potential impact that alternative statin regimens might have on a similar primary prevention population. For the end point of myocardial infarction, stroke, revascularization, or death, the 5-year NNT within JUPITER was 20 (95% CI, 14 to 34). All subgroups had 5-year NNT values for this end point below 50; as examples, 5-year NNT values were 17 for men and 31 for women, 21 for whites and 19 for nonwhites, 18 for those with body mass index <or=25 kg/m(2) and 21 for those with body mass index greater than 25 kg/m(2), 9 and 26 for those with and without a family history of coronary disease, 19 and 22 for those with and without metabolic syndrome, and 14 and 37 for those with estimated Framingham risks greater or less than 10%. For the net vascular benefit end point that additionally included venous thromboembolism, the 5-year NNT was 18 (95% CI, 13 to 29). For the restricted "hard" end point of myocardial infarction, stroke, or death, the 5-year NNT was 29 (95% CI, 19 to 56). In sensitivity analyses addressing the theoretical utility of alternative agents, 5-year NNT values of 38 and 57 were estimated for statin regimens that deliver 75% and 50% of the relative benefit observed in JUPITER, respectively. All of these calculations compare favorably to 5-year NNT values previously reported in primary prevention for the use of statins among hyperlipidemic men (5-year NNT, 40 to 70), for antihypertensive therapy (5-year NNT, 80 to 160), or for aspirin (5-year NNT, >300).
  
  
  CONCLUSIONS
  Absolute risk reductions and consequent NNT values associated with statin therapy among those with elevated high-sensitivity C-reactive protein and low low-density lipoprotein cholesterol are comparable if not superior to published NNT values for several widely accepted interventions for primary cardiovascular prevention, including the use of statin therapy among those with overt hyperlipidemia.
  
  
  BACKGROUND
  clinicaltrials.gov. Identifier NCT00239681.
authors.affiliation: Center for Cardiovascular Disease Prevention and the Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA. pridker@partners.org
authors.forename: Paul M
authors.initials: PM
authors.lastname: Ridker
authors.forename: Jean G
authors.initials: JG
authors.lastname: MacFadyen
authors.forename: Francisco A H
authors.initials: FA
authors.lastname: Fonseca
authors.forename: Jacques
authors.initials: J
authors.lastname: Genest
authors.forename: Antonio M
authors.initials: AM
authors.lastname: Gotto
authors.forename: John J P
authors.initials: JJ
authors.lastname: Kastelein
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Koenig
authors.forename: Peter
authors.initials: P
authors.lastname: Libby
authors.forename: Alberto J
authors.initials: AJ
authors.lastname: Lorenzatti
authors.forename: Børge G
authors.initials: BG
authors.lastname: Nordestgaard
authors.forename: James
authors.initials: J
authors.lastname: Shepherd
authors.forename: James T
authors.initials: JT
authors.lastname: Willerson
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Glynn
mesh_terms: D000367:Age Factors; D015992:Body Mass Index; D002097:C-Reactive Protein / Q000032:analysis*; D008078:Cholesterol, LDL / Q000097:blood*; D004311:Double-Blind Method; D023381:Endpoint Determination; D005260:Female; D005464:Fluorobenzenes / Q000627:therapeutic use*; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008297:Male; D024821:Metabolic Syndrome / Q000453:epidemiology; D009203:Myocardial Infarction / Q000453:epidemiology / Q000517:prevention & control*; D009204:Myocardial Revascularization; D011322:Primary Prevention; D011743:Pyrimidines / Q000627:therapeutic use*; D044469:Racial Groups; D012307:Risk Factors; D000068718:Rosuvastatin Calcium; D020521:Stroke / Q000453:epidemiology / Q000517:prevention & control*; D013449:Sulfonamides / Q000627:therapeutic use*
chemical_list: D008078:Cholesterol, LDL; D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium; D002097:C-Reactive Protein